Multitarget stool DNA test shows promise for early colorectal cancer detection

A recent prospective cross-sectional study in Thailand demonstrates that multitarget stool DNA testing is highly sensitive and specific for detecting colorectal cancer (CRC) among Thai individuals.

FDA approves J&J and Legend’s Carvykti for second-line multiple myeloma

The FDA has expanded the label for Johnson & Johnson and Legend Biotech’s multiple myeloma CAR-T therapy to make it a much earlier treatment option

April 7, 2024

3 Ways Prescription Tech Will Impact Providers’ Bottom Lines in 2024

Miranda Rochol, SVP for Provider Solutions at Prescryptive Health As a new year begins, there’s an opportunity on the horizon for health systems: the prescription

January 5, 2024

Targeted brain stimulation shows promise for treating TBI-related memory loss

Traumatic brain injury (TBI) has disabled 1 to 2% of the population, and one of their most common disabilities is problems with short-term memory. Electrical

July 18, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.